Health Research Methods, Evidence, and Impact


Feng Xie

BSc (Shanghai), MSc (Shanghai), PhD (Singapore)

Associate Professor, Department of Health Research Methods, Evidence, and Impact

CIHR New Investigator (2012-2017)

Associate Editor, Medical Decision Making

Deputy Editor, Health and Quality of Life Outcomes

Member, Centre for Evaluation of Medicine

905.522.1155 x 35808
fengxie@mcmaster.ca
www.phenomresearch.ca

On Campus:

HSC 2C11
1280 Main St. W.
Hamilton, ON, L8S 4K1

H306 Martha Wing
St. Joseph's Healthcare Hamilton
50 Charlton Ave E
Hamilton, ON, L8N 4A6

Academic Interests

Dr. Feng Xie is an Associate Professor of Health Economics in the Department of Health Research Methods, Evidence, and Impact, McMaster University. His research interests include economic evaluations using model and/or clinical trial data, health related quality of life and health preference measures, and design of cost effectiveness randomized trials. Dr. Xie is particularly interested in developing new methods related to health preference elicitation. He has applied these methods to chronic health conditions such as arthritis, cardiovascular diseases, cancer, Alzheimer’s disease, and diabetes. Dr. Xie has conducted numerous new health technology assessments to support federal and provincial reimbursement decision making. Dr. Xie is also intensively involved in measuring patient-reported outcomes alongside randomized clinical trials, as part of routine clinical practices, and for cost effectiveness analysis.

Current HRM Graduate Students

Manraj Kuar (PhD)
Xuejing Jin (PhD)
Bruno Kovic (PhD)
Pimwara Tanvejsilp (PhD)

Selected Publications

    1. Xie F, Pullenayegum EM, Gaebel K, Bansback N, Bryan S, Ohinmaa A, Poissant L, Johnson JA. A TTO-derived value set of the EQ-5D-5L for Canada, Medical Care, in press.
    2. Pullenayegum EM, Chan K, Xie F. Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach. Medical Decision Making, 2015 Epub ahead of print.
    3. Kovic B, Xie F, Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. Journal of Clinical Oncology, 2015; 33(20):2296-2302.
    4. Xie F, Pickard AS, Krabbe PF, Revicki D, Viney R, Devlin N, Feeny D. A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE). PharmacoEconomics, 2015;33(8):867-877.
    5. Xie F, The Economics of Adalimumab for Ulcerative Colitis. Expert Review in Pharmacoeconomics and Outcomes Research 2015;15(3):373-7.
    6. Krabbe PF, Devlin NJ, Stolk EA, Shah KK, Oppe M, van Hout B, Quik EH, Pickard AS, Xie F. Multinational evidence of the applicability and robustness of discrete choice modeling for deriving EQ-5D-5L health-state values. Medical Care. 2014;52(11):935-943.
    7. Xie F, Gaebel K, Perampaladas K, Doble B, Pullenayegum E. Comparing EQ-5D Valuation Studies: A Systematic Review and Methodological Reporting Checklist. Medical Decision Making 2014;34:8-20.
    8. Xie F, Hopkins RB, Burke N, Habib M, De Angelis C, Pasetka M, Giotis A, Goeree R. Time and labour costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: A time and motion study. Hospital Practice 2014;42(2):38-45.
    9. Xie F, Pullenayegum E, Gaebel K, Oppe M, Krabbe PF. Eliciting preferences to the EQ-5D-5L health states: discrete choice experiment or multiprofile case of best-worst scaling? European Journal of Health Economics 2014;15(3):281-288.

Search for citations for Dr. Xie on PubMed